The Medical Countermeasures Initiative (MCMi) is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response, led by the Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist.
FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure.
Together with U.S. government partners through the Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise, FDA helps define and prioritize requirements for MCMs in public health emergencies. This includes coordinating research, setting deployment and use strategies, and facilitating access to MCMs.
Information in this Section
MCMi News and Events
Medical countermeasure-related news and events, updated almost daily
What are Medical Countermeasures?
MCM questions and answers, including FDA's role and MCM use in emergencies
Publications and Reports
Reports from MCMi and partners
MCMi fact sheet(PDF - 358KB)
One-page printable fact sheet about MCMi
Subscribe to MCMi email updates, and view previous newsletters
Frequently Requested MCMi Links
Most-requested links from MCMi and the FDA Office of Counterterrorism and Emerging Threats
Medical Countermeasure Resources
Links related to MCMs and preparedness from FDA and government partners
Meet MCMi: Faces Behind the Initiative
Meet some of the people who help MCMi protect national health and security
FDA launched MCMi in 2010 - learn more about the program's history
MCMi News Archive
Archive of MCMi-related news by year since 2011
MCMi Events Archive
Archive of MCMi-related events by year since 2010
FDA's strategic priorities include medical countermeasures and emergency preparedness